Table 1.
Current DNA product Phase I to III open clinical trial targets
| Number of open trials | Category | Diseases and conditions treated |
|---|---|---|
| Phase I | ||
| 54 | Cancer | Melanoma, glioblastoma, lymphoma, cancer cachexia, acute lymphoblastic leukaemia, head and neck squamous cell carcinomarenal cell carcinoma, chronic lymphocytic B leukaemia, Hodgkins lymphoma, and colorectal, prostate, pancreatic, lung and breast cancer |
| 6 | Cardiovascular | Re-endothelialization, claudication, limb ischaemia, angiogenesis and Buerger disease |
| 5 | Healthy volunteers | HIV vaccine safety |
| 2 | Infectious disease | Chronic hepatitis B and HIV-1 |
| 1 | Neurological | Effect of human insulin-like growth factor for cubital tunnel syndrome |
| 1 | Ocular | Retinitis pigmentosa |
| 3 | Other | Erectile dysfunction, type I diabetes mellitus and overactive bladder syndrome |
| Phase II | ||
| 10 | Cancer | Melanoma, angioendothelioma, squamous cell carcinoma of the head and neck, lung cancer, mantle cell carcinoma and pancreatic adenocarcinoma |
| 4 | Cardiovascular | Claudication (cramp-like pains in the legs cause by poor circulation), peripheral ischaemic ulcers, limb ischaemia |
| 3 | Neurological | Relapsing remitting multiple sclerosis, diabetic neuropathy and nerve conduction velocity |
| 3 | Ocular | Atrophic macular degeneration and retinitis pigmentosa |
| Phase III | ||
| 1 | Cancer | Lung cancer |
| 1 | Cardiovascular | Limb ischaemia |